News Releases

08 Oct '21
Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics' SNIPRx platform for molecular selection of tumors for therapy with RP-3500 Favorable and differentiated safety profile, along with promising and distinct early activity, offer clear direction for future
07 Sep '21
Former CEO of Five Prime Therapeutics brings over 25 years of leadership and commercial experience in pharma, biotech and molecular Dx CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Sep. 7, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage
Displaying 1 - 10 of 17